Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes
Genetic Testing and Molecular Biomarkers · 01.01.2024 · 28 (1) · 2-9
DOI: 10.1089/gtmb.2023.0386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetic Testing and Molecular Biomarkers, erschienen am 01.01.2024. Verfasst von Fatma Nur Korkmaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye. Hauptthemen laut MEDLINE: HLA-C Antigens, Thyroiditis, Subacute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
There are several studies investigating the role of human leukocyte antigens (HLA) in the development and recurrence of subacute thyroiditis (SAT). The HLA subtypes associated with SAT were usually determined in a population-based manner and HLA-B*35, HLA-B*18:01, HLA-C*04:01, and HLA-DRB1*01 were detected to play a role in the disease susceptibility and prognosis. The aim of this study was to determine HLA alleles associated with the tendency of recurrence and prevention of SAT within the Turkish population.
Methods
This prospective study was conducted with 51 SAT patients and 720 healthy bone marrow donor volunteers. HLA-A, -B, -C, -DRB1, and -DQB1 were genotyped using next-generation sequencing.
Results
The frequency of HLA-A*02:09, HLA-B*35:01/35:02/35:03, HLA-C*04:01, HLA-DRB1*12:01, and DRB1*13:03 were associated with an increased risk of SAT development (Odds Ratio: 22.4, 9.5, 10.3, 4.2, and 3.5, respectively). While HLA-A*02:09, HLA-B*35:01, HLA-B*44:02 HLA-C*07:18, and HLA-C*16:04 were associated with nonrelapsing SAT, HLA-DR*12:01was associated with relapsing SAT. HLA-B*35:02, HLA-B*35:03, and HLA-C*04:01 were more frequent both in relapsing and nonrelapsing groups according to control group. The frequency of HLA-B*18:01, reported as a risk factor previously, was similar in the SAT and control groups (p = 0.959). HLA-DRB1*11:01 was associated with a lower risk of SAT development.
Conclusions
Along with -B*358 and -C*04, HLA-A*02:09 was detected as an important risk factor for SAT development in our population. HLA-DRB1*11:01 appears to be the protective HLA subtype against SAT. HLA-A*02:09, HLA-B*35:01, HLA-B*44:02, HLA-C*07:18, HLA-C*16:04, HLA-DQ*06:03, and HLA-DR*12:01 subtypes can establish a tendency to relapsing or nonrelapsing SAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Türkiye.
- Tissue Typing Laboratory, Department of Internal Medicine, Hematology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
- Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Türkiye.
ORCID-Profile: Fatma Nur Korkmaz
Zitieren
APA
Korkmaz, F. N., Gökçay Canpolat, A., Dalva, K., Elhan, A. H., Şahin, M., Çorapçıoğlu, D., & Demir, Ö. (2024). Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes. Genetic Testing and Molecular Biomarkers, 28(1), 2-9. https://doi.org/10.1089/gtmb.2023.0386
Vancouver
Korkmaz FN, Gökçay Canpolat A, Dalva K, Elhan AH, Şahin M, Çorapçıoğlu D, et al. Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes. Genetic Testing and Molecular Biomarkers. 2024;28(1):2-9. doi:10.1089/gtmb.2023.0386
BibTeX
@article{Korkmaz2024,
author = {Korkmaz, Fatma Nur and Gökçay Canpolat, Asena and Dalva, Klara and Elhan, Atilla Halil and Şahin, Mustafa and Çorapçıoğlu, Demet and Demir, Özgür},
title = {Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes},
journal = {Genetic Testing and Molecular Biomarkers},
year = {2024},
volume = {28},
number = {1},
pages = {2--9},
doi = {10.1089/gtmb.2023.0386}
}
EUVIMED